Financials in USD. Standardized financial statements.
A compact view of how MYND Life Sciences Inc. turns revenue into operating income and net income.
| Metric | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Revenue? | $92,990 | $0 | $0 | $0 | $0 |
| Revenue Growth? | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $332,990 | $180,000 | $0 | $0 | $0 |
| Gross Profit? | -$240,000 | -$180,000 | $0 | $0 | $0 |
| Gross Margin? | -258.1% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $1.59M | $2.88M | $4.29M | $56,466 | $2,535 |
| Operating Income? | -$1.83M | -$3.00M | -$4.29M | -$56,466 | -$2,535 |
| EBITDA? | -$1.83M | -$3.06M | -$4.28M | $0 | $0 |
| Income Before Tax | -$1.52M | -$3.70M | -$4.54M | -$56,466 | -$2,535 |
| Income Tax Expense | $0 | -$129,946 | -$168,308 | $0 | $0 |
| Net Income? | -$1.52M | -$3.57M | -$4.37M | -$56,466 | -$2,535 |
| EPS? | $-0.03 | $-0.08 | $-0.10 | $-0.00 | $-0.00 |
| Diluted EPS? | $-0.03 | $-0.08 | $-0.10 | $-0.00 | $-0.00 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality